Back to Search Start Over

Parental risk factors for fever in their children 7–10 days after the first dose of measles-containing vaccines

Authors :
Kristin Goddard
Ousseny Zerbo
Karin Bok
Edwin Lewis
Sharareh Modaressi
Hayley A. Gans
Nicola P. Klein
Source :
Human Vaccines & Immunotherapeutics
Publication Year :
2019
Publisher :
Informa UK Limited, 2019.

Abstract

We evaluated whether parental clinical conditions were associated with fever after a first dose of measles-containing vaccine (MCV) in the child in a cohort study including 244,125 children born in Kaiser Permanente Northern California between 2009 and 2016 who received MCV between ages 1 and 2 years. Each child was linked with his/her mother and father when possible. Parental clinical conditions present before and after their child’s birth were identified. We defined fever in the children as clinic and emergency department visits with a fever code 7–10 days after a first dose of MCV (“MCV-associated fever”). We evaluated parental clinical conditions associated with MCV-associated fever using multivariate logistic regression analyses. After adjusting for multiple factors, including healthcare utilization, maternal fever [odds ratio (OR) = 1.19, 95% confidence interval (CI) 1.06–1.32], fever after MCV (OR = 5.90, 95% CI 1.35–25.78), respiratory infections (OR = 1.20, 95% CI 1.10–1.31), migraine (OR = 1.14, 95% CI 1.05–1.24), syncope (OR 1.14, 95% CI 1.01–1.27), and essential thrombocythemia (OR = 1.93, 95% CI 1.15–3.25) were significantly associated with MCV-associated fever. Paternal respiratory infections (OR = 1.15, 95% CI 1.05–1.27), fever associated with respiratory infections (OR = 1.47, 95% CI 1.23–1.76), and vitiligo (OR = 1.63, 95% CI 1.06–2.53) were significantly associated with MCV-associated fever. Parental clinical conditions, specifically fever alone and fever associated with respiratory infection, are associated with fever in their child 7–10 days after MCV.

Details

ISSN :
2164554X and 21645515
Volume :
16
Database :
OpenAIRE
Journal :
Human Vaccines & Immunotherapeutics
Accession number :
edsair.doi.dedup.....1e3fb061d39dc006ae756a5be497aa34
Full Text :
https://doi.org/10.1080/21645515.2019.1675458